^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AT101

    i
    Other names: AT101, AT 101, AT-101
    Company:
    AbClon
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    12ms
    Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study. (PubMed, Mol Cancer)
    We developed a novel, safe, and potent CART19 product that recognizes a membrane-proximal domain of CD19 with fast on- and off-rates and showed significant efficacy and promising safety in patients with relapsed B-cell NHL.
    P1 data • Journal • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    AT101
    1year
    A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (ASH 2023)
    All pts received lymphodepletion with intravenous fludarabine (250 mg/m2) and cyclophosphamide (25 mg/m2) on days -4, -3, and -2. In this first-in-human phase I trial, AT101 was tolerable with limited and manageable toxicities. Notable preliminary efficacy was observed at the RP2D with no evidence of disease relapse after achieving a CR. These results warrant the pursuit of the planned phase II expansion cohort.
    Clinical • P1 data • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD19 mutation
    |
    cyclophosphamide • fludarabine IV • AT101
    over1year
    A Novel CD19-directed car t cell therapy (AT101) targeting a pristine membrane-proximal epitope under phase I clinical trial (ICKSH 2023)
    Currently, h1218-CART19 (AT101) is in a phase 1 clinical trial in Korea for relapsed and refractory B-cell Non-Hodgkin’s lymphoma patients. Keyword : CD19, CAR T cells, Lymphoma
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression • CD19 mutation
    |
    AT101
    over1year
    An open label, dose escalation, phase 1 study of AT101, a novel CD19-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (AACR 2023)
    The primary objective is to determine the safety, the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of AT101 in participants following lymphodepletion with cyclophosphamide and fludarabine (250 mg/m2 and 25 mg/m2). As of January 11, 2023, AT101 has been infused to six patients in cohort 1 and three patients in cohort 2. Detailed results will be presented at the meeting.
    Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression • CD19 mutation
    |
    cyclophosphamide • fludarabine IV • AT101